Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2010 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.9%

Alnylam Pharmaceuticals reported a smaller-than-expected loss per share, which was a positive surprise for investors. However, the stock still fell by 1.9%, likely due to a lack of revenue data and no guidance for the future. Investors may be cautious as they await more concrete information on financial performance and future expectations.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.29	N/A	+3.33%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed optimism about the company's ongoing projects and pipeline advancements. They emphasized their commitment to innovation.

We are encouraged by our progress in advancing our pipeline.

Our focus remains on delivering innovative therapies.

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.9%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Down 1.9%

Key numbers

Management commentary